Umesalma, S., Kaemmer, C., Kohlmeyer, J., Letney, B., Schab, A., Reilly, J., Sheehy, R., Hagen, J., Tiwari, N., Zhan, F., Leidinger, M., O'Dorisio, T., Dillon, J., Merrill, R. A., Meyerholz, D. K., Perl, A. L., Brown, B., Braun, T. A., Scott, A., Ginader, T., Zamba, K. D., Howe, J. R., Strack, S., Bellizzi, A., Goutham Narla, G., Darbro, B., Quelle, F., Quelle D. (2019). RABL6A Inhibits Tumor-suppressive PP2A/AKT Signaling to Drive Pancreatic Neuroendocrine Tumor Growth. Journal of Clinical Investigation, DOI: 101172/JCI123049

Scott AT, Weitz M, Breheny PJ, Ear PH, Darbro B, Brown BJ, Braun TA, Li G, Umesalma S, Kaemmer CA, Maharjan CK, Quelle DE, Bellizzi AM, Chandrasekharan C, Dillon JS, O'Dorisio TM, Howe JR. Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors. Clin Cancer Res. 2020;26:2011-21. PubMed PMID: 31937620; PMCID: PMC7165057.

Menda, Y., Madsen, M. T., O'Dorisio, T. M., Sunderland, J. J.,  Watkins, G. L., Dillon J. S., Mott, S., Zamba, K. D. , Schultz, M. K., Bushnell, D. L., O'Dorisio, M. S. (2018). 90 Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy. Journal of Nuclear Medicine, 59(11), 1692–16984)

Keck KJ, Breheny P, Braun TA, Darbro B, Li G, Dillon JS, Bellizzi AM, O'Dorisio TM, Howe JR. Changes in gene expression in small bowel neuroendocrine tumors associated with progression to metastases. Surgery. 2018;163:232-9. PubMed PMID: 29154080; PMCID: PMC5736454.

Menda, Y., O'Dorisio, T. M., Howe, J. R., Schultz, M., Dillon, J. S., Dick, D., Watkins, G. L., Ginader, T., Bushnell, D. L., Sunderland, J. J., Zamba, K. D., Graham, M., O'Dorisio, S. M. (2017). Localization of Unknown Primary Site with 68 Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumor. The Journal of Nuclear Medicine, EPUB PMID 28153957